JPS62289515A - Lint fabric having surface coated with drug - Google Patents
Lint fabric having surface coated with drugInfo
- Publication number
- JPS62289515A JPS62289515A JP13312086A JP13312086A JPS62289515A JP S62289515 A JPS62289515 A JP S62289515A JP 13312086 A JP13312086 A JP 13312086A JP 13312086 A JP13312086 A JP 13312086A JP S62289515 A JPS62289515 A JP S62289515A
- Authority
- JP
- Japan
- Prior art keywords
- drug
- cloth
- lint
- coated
- lint cloth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000004744 fabric Substances 0.000 title claims abstract description 81
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 229940079593 drug Drugs 0.000 title claims abstract description 63
- 239000011248 coating agent Substances 0.000 claims abstract description 30
- 238000000576 coating method Methods 0.000 claims abstract description 18
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 6
- OKJPEAGHQZHRQV-UHFFFAOYSA-N iodoform Chemical compound IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229920000742 Cotton Polymers 0.000 claims abstract description 4
- 239000000835 fiber Substances 0.000 claims abstract description 4
- 239000004745 nonwoven fabric Substances 0.000 claims abstract description 3
- 102000008186 Collagen Human genes 0.000 claims abstract 2
- 108010035532 Collagen Proteins 0.000 claims abstract 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract 2
- 238000005266 casting Methods 0.000 claims abstract 2
- 229920001436 collagen Polymers 0.000 claims abstract 2
- 238000007646 gravure printing Methods 0.000 claims abstract 2
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 claims abstract 2
- 229960004068 hexachlorophene Drugs 0.000 claims abstract 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 28
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 210000001124 body fluid Anatomy 0.000 claims description 6
- 239000010839 body fluid Substances 0.000 claims description 6
- 230000007721 medicinal effect Effects 0.000 claims description 6
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 4
- 229920000153 Povidone-iodine Polymers 0.000 claims description 4
- 238000005516 engineering process Methods 0.000 claims description 4
- 229960001621 povidone-iodine Drugs 0.000 claims description 4
- 230000000202 analgesic effect Effects 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000004659 sterilization and disinfection Methods 0.000 claims description 3
- IYLLULUTZPKQBW-UHFFFAOYSA-N Acrinol Chemical compound CC(O)C(O)=O.C1=C(N)C=CC2=C(N)C3=CC(OCC)=CC=C3N=C21 IYLLULUTZPKQBW-UHFFFAOYSA-N 0.000 claims description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 claims 1
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 claims 1
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 1
- 229920000858 Cyclodextrin Polymers 0.000 claims 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims 1
- HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 claims 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims 1
- 239000002390 adhesive tape Substances 0.000 claims 1
- 230000001139 anti-pruritic effect Effects 0.000 claims 1
- 239000003908 antipruritic agent Substances 0.000 claims 1
- 229960005274 benzocaine Drugs 0.000 claims 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 claims 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 claims 1
- IVHBBMHQKZBJEU-UHFFFAOYSA-N cinchocaine hydrochloride Chemical compound [Cl-].C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCC[NH+](CC)CC)=C21 IVHBBMHQKZBJEU-UHFFFAOYSA-N 0.000 claims 1
- 230000003749 cleanliness Effects 0.000 claims 1
- 229960004022 clotrimazole Drugs 0.000 claims 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960003957 dexamethasone Drugs 0.000 claims 1
- 229940045574 dibucaine hydrochloride Drugs 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- 229960003645 econazole nitrate Drugs 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims 1
- 229960000905 indomethacin Drugs 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 229960004194 lidocaine Drugs 0.000 claims 1
- 229960005040 miconazole nitrate Drugs 0.000 claims 1
- 239000000820 nonprescription drug Substances 0.000 claims 1
- 229940068984 polyvinyl alcohol Drugs 0.000 claims 1
- 238000007639 printing Methods 0.000 claims 1
- 229960001309 procaine hydrochloride Drugs 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 7
- 239000002562 thickening agent Substances 0.000 abstract description 2
- 230000000857 drug effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 238000001771 vacuum deposition Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 13
- 239000007788 liquid Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 7
- 239000002674 ointment Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 208000017520 skin disease Diseases 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229930003836 cresol Natural products 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000000518 rheometry Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 108700009560 Bacteria Q Proteins 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000448053 Toya Species 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000895 deafness Toxicity 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000006303 photolysis reaction Methods 0.000 description 1
- 230000015843 photosynthesis, light reaction Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000008149 soap solution Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000004078 waterproofing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
(イ)産業上の利用分里チ
本発明8よ医薬品産業の分エチζこ属し〜医療の士易で
皮膚の意す傷〜炎症に対し〜殺菌?肖毒薬〜消炎薬とし
て利用さねへ虫さされ等に対しては鎮痛薬として不り用
さ?L、イI農を生疾患に対しては殺菌薬〜そして痛み
に対してζよ〜鎮痛薬として千〇用される事を目的とし
た奔シ別を7kに可?容な才占・(生物質の外」舜夜に
?容解あるし)ζよ混入し〜その水溶液をリント布の表
面にイ寸着させ乾燥して〜薬剤を物理日勺〜イヒ学自勺
に安定させた薬剤コーチインク−リント布の製造法に関
するものであり〜更にその薬剤コーティングリント布を
皮石患音図こ貼布した士烏合〜薬剤カベリント布の表面
ζこコーティングされて(/″するため、皮虜患CIK
6”ら浸出〜漏出した体液力炒量のす烏合−あるし)ζ
ま患g(5を唾液で湿らせる程度の少量の7に分であっ
ても〜速や力1に薬剤が溶出して薬物の薬効が皮眉患音
トクこ奏効することを特徴とする薬剤コーティングリン
ト布の製造に関するものである。[Detailed Description of the Invention] (a) Industrial Applications This invention 8 belongs to the pharmaceutical industry. - In medical practice, against skin wounds - Inflammation - Sterilization? Poison medicine ~ Used as an anti-inflammatory medicine Is it not used as an analgesic for insect bites, etc.? L, Is it possible to add 7k to a drug that is intended to be used as a bactericidal agent for raw diseases and as an analgesic for pain? A good fortune-telling (outside of biological matter) Shunya? It is understandable) mix it with ζ ~ apply the aqueous solution to the surface of a lint cloth and dry it ~ the drug from the physical sciences ~ Ihi Gakuji. This relates to a method for producing a drug-coated ink-lint cloth that has been stabilized with a drug coated cloth. “To do so, skin captive CIK
6" leaching ~ the amount of leaked body fluids - there is) ζ
A drug that is characterized by its medicinal effect on the skin and eyebrows as the drug dissolves quickly and forcefully even in a small amount of 7 minutes, such as moistening the drug with saliva. It relates to the production of coated lint fabrics.
(ロ)従来の技f/トチ
リント布とCよ本3柾医療の+易でイ吏ねれる傷口の保
護〜薬物〜ギフ゛スの保持及び患合トの固定等に使用さ
れる布を示す力(その具備条件としてζま〜清潔〜柔軟
〜丈夫で〜通気1生、吸湿・を生を有した物である。(B) Conventional techniques f/Totilinto cloth and C. Medical treatment: Protection of easily damaged wounds ~ Drugs ~ Power showing the cloth used for holding gifts and fixing patients, etc. The requirements are that it is clean, flexible, durable, breathable, and moisture absorbent.
ヨードホルムを特徴とする特1午δ青求の範囲〜第3項
に示した薬剤の個々の組成〜性4犬〜薬効〜=1作用番
こつむ)てζま既に医薬品として使用された事があり〜
現在も使用されてむするものcホ力1りである為〜有効
゛を生〜安全11生につ0ては公知のもの4f力1りで
ある。しカーしなめ(ら組み合せによる可2生が全て確
力)められてム為るものば力1りでなく不明のものも多
い。The range of special features characterized by iodoform ~ Individual composition of the drugs shown in Section 3 ~ Sex 4 ~ Medicinal efficacy ~ = 1 Action number Kotsumu) has already been used as a medicine. can be~
The one that is still in use today has only one force, so it is effective and safe. There are many things that are unknown, not just power, that can be defeated by Shikarame (all combinations of K2 and R are certain).
現在リント布と薬剤が合体されたものとして番よ(A)
湿布薬と(B)アクリノールカ゛−ゼ′にイ曵表される
)渋な7尺ン容・I生の薬剤を含?是させた綿布カベあ
る。Currently, it is a combination of lint cloth and medicine (A)
It contains poultices and (B) astringent 7-inch liquid medicines (represented by acrinol case). There is a made-up cotton wall.
前者(A)ζよリント布の上に軟膏を展延させたもので
あり皮膚に貼布することによって軟膏中の揮敗匹冑効成
分をα II ”T”−(密圭ヰ包帯?去)効果ζこよ
って皮膚力Aら吸11又させ一筋肉あるし)ζ′;!:
金中経ζこイ′μ用して鎮痛効果を発揮するものである
力\本発明と比咬すると湿布薬は有効成分である薬剤が
経時的に安定でなく〜気密容84こ保存せね4ぼならな
い。又一度開封した機密容器中の湿布用Ω′−ることカ
ベ出来ずイ建康な月几にし力)貼布〜使用することが出
来なc/)。n口ち安定・r生の保↑寺とイ史用方法カ
ベ限定されてしする。The former (A) is an ointment spread on a lint cloth, and by applying it to the skin, the volatile ingredients in the ointment are removed. )Effect ζTherefore, there is one muscle that increases skin strength A and 11))ζ′;! :
In contrast to the present invention, the active ingredient in poultices is not stable over time - it must be stored in an airtight container for 84 hours. 4. Don't fall. Also, once the compress is in a sealed container that has been opened, it cannot be applied or used. The method of use for temples and history is limited to the stability of n-mouth and r-life.
軟膏剤の欠点の一つは、軟膏中に配合された有効成分で
ある薬剤が充分利用されず大部分は軟膏中に残ったまま
で存在する点にある。One of the drawbacks of ointments is that the active ingredient, the drug, contained in the ointment is not fully utilized and most of it remains in the ointment.
湿布薬と類似のものにプラスター剤□
膏灼カベある力(これζま湿布薬ど同じ1追に使用方法
力市随コされている点と、薬剤を保↑青してし)る支↑
寺布カベリント布としての条件を具イノ苛し1与なGA
点に異なるが点ある。Similar to poultices, plasters have the same power as plasters.
The conditions for temple cloth coverinto cloth have been thoroughly tested by GA.
There are different points, but there are points.
f&者CB)ζま液体である薬剤を皮府患合シζこ使用
するV−祭〜薬剤力<、 #B!こ流れ落ちな(、s工
夫として用いられている訳で〜その便法としてガーゼ−
綿花等からなるリント布を用G″%てし)るζこすぎな
む)。f & person CB) V-festival ~ drug power <, #B! This is used as a trick to prevent it from flowing down. As an expedient, gauze
A lint cloth made of cotton, etc. is used.
従ってリント布に薬剤をコーティングしその薬剤を物理
8勺番こもイヒ学日勺ζこも安定な1犬態で保持し一使
用時にすぐ役立つようなものζま未だに見あたらなし1
゜(
ハ)発明が解決しようとする問題点し
たがって従来の医薬品で一皮膚患f阪局所に直接作用す
る薬剤でリント布にコーティングされたものc′;!:
なむ)。皮膚患音68こ直接作用する薬剤をリント布に
コーティングしたものを作成〜使用しようと思えば一以
下の様な問題点がある。Therefore, I have yet to find anything that coats a lint cloth with a drug, holds the drug in a stable state, and is immediately useful when used.
゜(c) Problems to be solved by the invention Therefore, conventional pharmaceutical products are those coated on lint cloth with drugs that act directly on the affected area of the skin.c';! :
Namu). If you try to create or use a lint cloth coated with a drug that acts directly on the skin, there are the following problems.
(a)リント布の柔軟・を生ζこ添う3軍力・を生のあ
るコーティングでなければならない。(a) The coating must be flexible and flexible to the lint cloth.
(′b)リント布とコーティングされた薬剤力<祭り離
−月先着して?、まならなむ)。('b) Drug power coated with lint cloth < festival release - first come first served? , Mananamu).
(C)コーティングされた薬剤が安全で且つ有効な状態
を長期ζこ保持されて(−%な番すれIffならない。(C) The coated drug must remain safe and effective for a long period of time (-%).
快定・tす
(d)、FelJ口患gBに使用した時〜速や力)に効
果カベ発揮されね4ぼならなむ1゜
(e)薬剤が薬効を奏効した後も〜リント布ζまリント
布の役目を果たさなければならなむ)。(d) When used for FelJ mouth problems (speed and force), the effect is exerted even after the drug has taken effect (e) Lint cloth ζ (It must act as a lint cloth.)
(f)皮J”−1tにイ寸着した薬剤の洗む)流しが容
易である。(f) Washing of chemicals applied to the skin is easy.
これらの点を解決しなりナれCホ〜従来力Aら〜皮膚患
gBのt台療ζこ薬剤とリント布力<男す々ζこ使用さ
れてl、sた事とイ町ら変りなく〜偵弥りさも退謬村生
も見出すことが出来なG)。To solve these points, it is necessary to solve these problems.The medicine and lint cloth used in the treatment of skin ailments have changed since then. I can't find Risa Reiya or the retired Murao G).
(ニ)問題点を解決するための手段
本発明は〜これら従来の技術の問題点を解決して、医療
の場に役立たす医療品を開発することに成功した。(d) Means for solving the problems The present invention has succeeded in solving the problems of these conventional techniques and developing a medical product useful in medical settings.
!!pち〜皮膚患g′rSζこり之制傷あるむ)ζよ炎
症りこより浸出〜漏出する体液(zk分)があることに
着目し一生体の生理反応であるこれら現象を矛り用出来
なGA力1と考えた。! ! Focusing on the fact that there is body fluid (zk) that oozes or leaks from inflammation due to skin disease (g'rSζ stiffness and scarring), it is not possible to use these phenomena, which are physiological reactions of the body throughout life, as a countermeasure. I thought it was GA power 1.
次ζこオブラートが固形でありなカベらすぐ水りこ?容
ζナヘ*占着を生を有すること力)ら〜オブラートが薬
効を有する薬品であればそれを傷口に貼ることによって
効果があるのではなし1力1と考えた。し力1しなカベ
ら〜もしその事カベ可自旨であっても〜直接患音6りこ
薬を塗布することと上ヒ較し〜進歩性カベあるとζま思
えなかった。Is the next ζ oblate solid and watery right from the wall? I thought that if an oblate was a drug that had medicinal properties, it would be effective by applying it to a wound. However, even if it was possible to do so, I couldn't believe that there was an inventive wall compared to applying Riko medicine directly.
そこで〜患部を保護するリント布にオブラートの様なも
のがコーティングされておれば〜患部に薬を塗り〜患部
を保護すると云う2つの事が同時に出来る但弾すさと〜
その様なものが出来れば’3gBR〜携帯〜保管に包睡
りであると考えた。し力1しなカベら〜実験年吉果ζこ
よれ、=〜澱粉であるオフ−ラードは弓虫度力<6弓く
〜3単・を生りこ問題があって〜]:宜的力ロエ〜及び
使用に耐えられないこと力伴すった。Therefore, if the lint cloth that protects the affected area is coated with something like oblate, it will be able to do two things at the same time: apply medicine to the affected area and protect the affected area.
I thought that if something like that could be made, it would be a good idea to store the '3gBR as a cell phone. Shiriki 1 Shina Kabera ~ Experimental yearly fruit ζ Koyore, = ~ Starch O-lard is Yumushi degree power < 6 Bow ~ 3 single ・ There is a problem ~]: Gitoku power Roe ~ and the power involved was unbearable.
オフ−ラードよりも物王里口勺・性質りこイ憂れてしす
る〜ハイアミロスターチを使用する事も実!倹した力\
これ4ま経時変イヒカベ大で4〜5週間で変質すること
が知られて居るごとく〜経時安定性に於いて問題があっ
たー
同じような可?S’を生の1勿質として知られてし)る
ものにポリビニールアルコールカベ力(これζま粘・を
生が高くリント布ζこコーティングすることは容易に出
来る力(皮膚患部力1ら2畳出す布速な少量の水分でば
薬物力令容出し難く単独でζよイ吏む)難も)こと力伴
りった。It's more natural than off-lard! It's true that it uses high amylostarch! Thrifty power\
It is known that this changes over time, and changes in quality in 4 to 5 weeks.There was a problem with stability over time.Is it similar? Coating S' with a polyvinyl alcohol coating (known as a raw material) and a lint cloth with a high viscosity can easily be applied to the affected skin. A small amount of water as fast as 2 tatami mats was enough to get the drug out, and it was very difficult to use alone.
更にある種の成分においては〜薬物同志溶解ある0ζよ
混合することによつて性質力(少しづつ変わったものに
なること力伴すった。Furthermore, in certain types of ingredients, when mixed with each other, the properties of the drug gradually change.
イタリえるボッエノールやクレソ゛−ルζま塾已院して
コーティング薬剤の成分として不適である。Bochenol and cresol ζ are unsuitable as ingredients for coating agents.
これらの実験の繰り返し力1ら〜解決すべき問題点を解
決し〜実用に供して問題な(かつ包睡すなものを製造す
る方法を得た。本発明で調整したコーティング薬は〜リ
ント布の繊維に吸収されてしまうことなく〜リント布の
繊維毛足ζこ力1らむ程度で表面ζこ〜又アルミカ9停
間されたリント布ζこあって!よアルミ箔の表面に接着
した状態でコーティンク゛されるため〜リント重力1ら
祭1g廿、月梵着すること8よなG)〜リント布ζこt
恣う引i力・を生を合せI寺ってむするため皮府患音b
ζこ貼付する上烏合〜良(月ルに添G)〜 し力1も薬
剤1力(リント布の表面Qこコーティングされるため〜
2是出〜漏出した体液力炒量の上品合であっても薬効を
発車できる。Through the repetition of these experiments, we solved the problems that needed to be solved and obtained a method for producing a product that is problematic (and sleepable) by putting it into practical use.The coating agent prepared according to the present invention Without being absorbed by the fibers of the lint cloth, the fibers of the lint cloth can be applied to the surface with just one force.The lint cloth that has been coated with alumina for 9 times is also adhered to the surface of the aluminum foil. In order to be coated with ~ 1 g of lint gravity, it is necessary to wear it every month (G) ~ lint cloth ζ
To combine the force of attraction into life and call it a temple, it is a skin pain sound.
ζThe upper surface of the lint cloth to be pasted is good (G attached to the moon).The first force is also the first force of the drug (because the surface of the lint cloth is coated)
2. Even if the amount of leaked body fluid is high, it can produce medicinal effects.
本発明カベ成功したことζよ〜至適レオロジ3垣力・を
生のあるものを製造する方法を発見したこと。この水溶
液に溶解ある(、zl、ま混入して≧舌を生を失わずに
皮膚疾患ζこ有効・を生を発揮し得る薬剤を選択し〜実
証し1尋たこと。The success of this invention is the discovery of a method for producing a product with optimal rheology. We have selected and verified a drug that can be dissolved in this aqueous solution and be effective in treating skin diseases without losing the vitality of the tongue.
リント布ζこ:F、h=を生氏容液と有効・を生のある
薬剤とを混合調整したコーティング薬剤を布全体に浸み
込ませることな(〜布の表面にコーティングする方法を
発見したこと等を特徴とする製造法を発明したこと等力
(従来の技術の問題点を解決したものである。Lint cloth ζ: F, h = A method of coating the surface of the cloth was discovered by soaking the entire cloth with a coating agent prepared by mixing the liquid and the active agent. The invention of a manufacturing method that is characterized by the following characteristics (it solves the problems of conventional technology).
(ホ)ス功簡タリ及び実l■匁1
次にンド発明の実施方法と実験の昂吉果を(9!Jにあ
ζyて本発明の特徴を述べる力(本発明C’:l!:’
、″MJ餌9+18こ限定されるものでるよなG1゜其
功祠列 1
(a)まず−2kK倉付しトリク゛ルコ多糖(分子(b
吹に〜ポビドンヨード4gを〜水10rnlに?劉介し
たものを*占・tυに名訃夜にカロえ攪1半均−に溶解
せしめる。これをコーティング薬剤とする。(E) The method of carrying out the invention and the results of the experiments are described below (9! :'
, ``MJ bait 9 + 18 are limited.
Fukini~4g of povidone iodine~10rnl of water? Dissolve the mixed liquid in a half-ton of water with a stir on the evening of the night. This is used as a coating agent.
(C慮睨済したコーティング薬剤を?朶シ)トレーに入
れる。(C) Place the coated chemicals into the tray.
(d)リント布(布目か細かべ〜起毛の多くな(、%も
の)を巾30 c m(立にして巻ム)たリントのロー
ルを用意する。(d) Prepare a roll of lint with a width of 30 cm (rolled vertically) made of lint cloth (fine-grained to highly brushed).
(e)コーティング薬剤の入ったトレーの巾より少し狭
めで〜表面にす菜さ30pの糸田カーいメツシュのン品
のあるローラーを作成し、ローラーの回転によってロー
ラーの表面をつたわってコーティング薬剤が力1き上ζ
デられる様装置を方缶す。(e) Make a roller that is slightly narrower than the width of the tray containing the coating agent, and has a 30-p. force 1 more ζ
Prepare the device so that it will be removed.
(fXe順で作成したローラーの上■トζこ−同じ大き
さで表面がたむ)らなコーム製のローラーを装置して〜
先ζこ述べられたローラーの回転と逆りこ回転する様ζ
こする。(The surface of the roller made in fXe order is the same size as above).
The rotation of the roller described above and the manner in which it rotates in reverse
Rub.
(g)二つのローラーの間ζこリント布を力1ま−ピ送
り込むようにしてリント布を移動させることζこよって
〜リント布の片面にコーティング薬剤をイ寸着さ一仕る
〜(h
)コーチインク−薬剤が付着したリント布をP拠と風と
で乾燥させることによってリント布にコーチインクル薬
剤が定着し〜コーティングされる。(g) Move the lint cloth between the two rollers by feeding the lint cloth one stroke with one force.Thus, the coating agent is thoroughly applied to one side of the lint cloth. ) Coach ink - By drying the lint cloth to which the drug has adhered with P base and air, the coach ink drug is fixed on the lint cloth and coated.
(i)コーティングが完了したリント布cマ自由ζこ切
断が出来るため用途ζこ応じた大きさζこしてイ吏うこ
とカベ出来る。(i) Since the coated lint cloth can be cut freely, it is possible to cut the lint cloth into a size according to the intended use.
フカ=D守イタリ2
リント布にアルミを蒸若したものを使用する場合
水1004二対して〜 トリクールコ多糖(分子量20
0000)を25gトP−■−P (ホ”Jヒニールピ
ロリドン)5〜10gの範囲で混入−力ロ温〜攪(牢し
て粘性水溶液を作る。Hook = D Morita 2 When using steamed aluminum for lint cloth, water 1004 to 2 ~ Tricurcopolysaccharide (molecular weight 20
0000) in a range of 5 to 10 g. Stir at room temperature to make a viscous aqueous solution.
以下るま実卿タリー1と同、F食である力(アルミカ9
知冴されたリント布のこ゛とく表面力<上句−で布面の
+;a!こ毛足カベなくコーティングし英廿t、)i局
舎でも〜増粘剤をカロえることによって良くコーティン
グ出来〜その効果も変らない。The power that is F food (Armica 9
The special surface strength of the well-known lint cloth <+;a! It can be coated without any thick layer, and even in the case of an office building, it can be coated well by adding a thickener.The effect remains the same.
用途によっては速攻性が要求さねへまたゆっくりと長い
間効果力寸寺続されることを期i寺される上品合力(あ
る。これらの調整ζよ以下の方法によって調節すること
カベ出来る。Depending on the application, quick action may be required, or the resultant force may be expected to be slow and effective over a long period of time.These adjustments can be adjusted by the following method.
速攻・を生を上告す+見合
(a)トワクリレコ多糖の西己合上ヒを江叉する (7
尺ζこ混入する上ヒ率を下クデる)
(b)トリク゛ルコ多糖の分子量をより少なむ)物に変
える。Appeal the haste + matchmaking (a) Towakurirekopolysaccharide's Nishi-Kai-Ai-hi-hi (7)
(b) Change the molecular weight of triglycopolysaccharide to a substance with a lower molecular weight.
(C)大樋タリー1の(e順で述べたローラーの表面の
メツシュの溝の深さを浅くする。 ■いコーティングを
作る)
遅効性く1余効PtE)を期9寺する士烏合(a))Y
、lり゛ルコ多′JD9の西己合とヒを増加する(7k
に混入する上ヒ率を上番デる)
(1)) )リク゛ルコ多糖の分子量をより多し)もの
に変える。(C) In the gutter tally 1 (shallow the depth of the mesh grooves on the surface of the roller mentioned in order e. ■Create a thick coating). ))Y
, increase the number of Nishi-Kai and Hi in JD9 (7k
(1) Change the molecular weight of the liquid polysaccharide to one with a higher molecular weight.
(C)P−V−P、 −P−■−A−2午〜可?容・
を生の土亦F占剤を調云百しな力(らカ口える。(C) P-V-P, -P-■-A-2pm-possible? Yong・
It is said that the power of a hundred people is used to prepare the earth's natural power.
(d) 戴餌タリー1の(e順で述べたローラーの表面
のメツシュの?毒のf采さを?朶(する。 いいコーテ
ィングを作る)
以下るま力筒タリ1の方法に準じて作成することが出来
る。(d) Preparation of feeding tally 1 (to remove the poisonous texture of the mesh on the surface of the roller mentioned in order e). Create a good coating according to the method of feeding tally 1 below. You can.
実l函列−1
力祠タリー1の方ン去ζこよって作成した薬剤コーチイ
ンク′リント布の殺菌、?肖ミ釈効果を確認するため以
下の実験を実施した。本発明の方法ζこよって製造され
た薬剤コーチインターリント布の薬効の確認方法!ま〜
期1寺する薬効によって異なり一本実験(Fllζこよ
ってのみ確認されるものでりよな(〜多種の方法カベあ
る〜中にCよ長期の期間〜患者ζ二対して連続使用し〜
医[1市によって効果と副作用を確ユ忍−仕ねζぼなら
ぬ上烏合もある。従って本発明によって製造された〜薬
剤コーティングリント布の薬効確認の方法ζま本実験c
−3艮定されるものではない。Actual box array-1 Sterilization of the drug coach ink'lint cloth created by removing the method of Power Shrine Tally 1? The following experiment was conducted to confirm the effect of portraiture. A method for confirming the medicinal efficacy of the drug coach interlint fabric produced by the method of the present invention! Ma~
The medicinal efficacy varies depending on the medicinal effect and can only be confirmed by a single experiment (there are many different methods).
There are some cases where the effectiveness and side effects are difficult to ascertain depending on the doctor. Therefore, the method for confirming the medicinal efficacy of the drug-coated lint cloth produced according to the present invention
-3 It is not specified.
まずシャーレ−に寒天培地を作成し〜公知の方法(カッ
プ?去)りこより♀■菌Q蛎WiEB〜黄色ブドウ球勘
の発育阻止効果を〜既に薬理作用が公知のものとなって
いるポビドンヨードの10%水溶液を対照薬として比校
実顎してみた。その実霧吉果によると一力面タリー1の
方法によって製造された薬剤コーティンクパリント布の
糸田苗の発育阻止効果は〜対照薬と同等の効果を示した
。このことは一本発明の方法により製造された薬剤コー
ティングリント布カー15ff1里学0勺に有効である
ことを示している。First, prepare an agar medium in a Petri dish ~ using a known method (cup? leave) from Riko♀ ■ Bacteria Q oyster WiEB ~ inhibitory effect on the growth of Staphylococcus aureus ~ Povidone-iodine, whose pharmacological action is already known. A comparison was made using a 10% aqueous solution as a control drug. According to Yoshika Minori, the effect of inhibiting the growth of Itoda seedlings of the drug-coated pallint cloth produced by the method of Ichirikimen Tarry 1 was equivalent to that of the control drug. This indicates that the drug-coated lint cloth fabric produced by the method of the present invention is effective.
(へ)発明の構成 本発明を構成する要素は以下の通りである。(f) Structure of the invention The elements constituting the present invention are as follows.
(a)リント布の選定
医療の上易で使用されるリント布ζま力1なりの多種に
わたる力<−厚さが薄すぎるとうまく表面にコーティン
グすることが出来ず〜厚すぎると使用の場が限定される
。又〜布あるいは不織布でも目の粗いものはだめであり
〜目の1田力1も%厚さ1mm〜1−5mmのものが最
適であることを実験することて〜初めて確かめ得たこと
。(a) Selection of lint cloth A lint cloth used for medical purposes has a wide variety of forces. is limited. Also, I was able to confirm for the first time by experimenting that even cloth or non-woven fabrics should not have coarse mesh, and that the optimum thickness for each mesh is 1 mm to 1-5 mm.
(’b)コーティング薬剤の調整
*占3単・を生(レオロジー)を持つ物質Cま多、f重
あろう(その中から液体でかつ布の表面にコーティング
が出来〜そのコーティング薬剤が乾燥固型イヒした1に
&こも少量の水分て可逆的ζこ易?8である・を生眞を
(寺った物質を発見し一数回の実験の繰り返しによって
一最も適当なコーティング薬剤を調整することに成功し
たことである。このことにより出来上刃(ったものが固
体であるζこも力飄力1わらず液体と同様の効果が生ま
れることになった。('b) Adjustment of coating agent *There are many substances with rheology such as 3, 3, and 4 (from which a liquid can be formed and a coating can be formed on the surface of the cloth ~ the coating agent dries and hardens). It is easy to reversibly use a small amount of water in the mold 1. After discovering a suitable material and repeating the experiment several times, the most suitable coating agent is prepared. This resulted in the creation of an effect similar to that of a liquid, even though the finished blade was solid.
そのイ曵表n勺コーティング薬剤りよ(カ戊り毬丹遺紗
尺75g〜 トリク゛ルコ多糖(デドト量20万)25
g、ポビドンヨード4g)の書!I合で混合したもので
ある。(−e表的失敗イタリであるコーティング薬剤は
く滅菌精製水75g〜トリク゛ルコ多糖(分子量20万
)25g。Its first surface is the coating drug (75g ~ triglycopolysaccharide (dedot amount 200,000) 25
g, povidone iodine 4g) book! It was mixed in the I-mixture. (-e) The coating agent, which was an apparent failure, was removed from 75 g of sterilized purified water to 25 g of triglycopolysaccharide (molecular weight 200,000).
クレソ゛−ル石鹸液20m1)の害1合で混合したもの
であり〜凝固物が液体中に現出した。It was mixed with 20 ml of cresol soap solution, and a coagulum appeared in the liquid.
(C)有効成分のスクリーニング
リント布の表面にコーティングすると云う特殊な加エエ
f呈を必要とするため皮膚患954こン台療目的でイ吏
用し9尋る膵づ団力と≧てイ炉出来る訳でりまなc/)
。i2r]ちカロ7に分MGをしなし1もの〜加熱分解
をしないもの〜光分解をしなむ)もの−自己合皮イヒを
起こさなし)もの−更にpH中性附近で安定なもので*
計を生水溶液に土仔−分散し〜有効・を生を損わなG)
ものを〜スクリーニンク゛して得たことであり〜これら
?、よ実験ζこよってし力婢すらな力1ったものカベ多
(含まれる。(C) Screening of active ingredients Because it requires a special treatment such as coating the surface of a lint cloth, it is used for the treatment of skin disorders and has a 954% effect on the pancreatic gland force. I can make a furnace c/)
. i2r] Add MG for 7 minutes to 100% - Items that do not decompose by heat - Items that do not undergo photolysis - Items that do not cause self-synthesis - Items that are stable at around pH neutral *
Disperse the liquid in a raw aqueous solution to make it effective and do not damage the raw material.
These are the things I got from screening things. , the experiment ζ has been carried out with a lot of power (including a lot of things).
(d) Ep届す技多野を応用したコーティング方法。(d) Coating method applying Gitano Ep delivery.
布ζこコーティングする技律テとしてCよ、防水力口二
カくまず想像出来〜次む)でツーリント柄の月艮土也を
想イ象すると、思われる。む)ずれζこしても、これら
の技fzr−?ζよ、一度コーティンク゛をh缶したら
出来るだるす?8出したり〜剥離〜月修普しなG″%1
謀を願ってG−する。As for the technique of coating cloth, I can easily imagine the waterproofing power (Next), and when I imagine the Tourinto patterned Tsukiwa Toya. M) Even if the shift is ζ, these techniques fzr-? ζ, once you apply a can of coating, will you be able to do it? 8 out ~ Peeling ~ Monthly repair G''%1
G- in hopes of success.
し力1しなカベら〜本発明Cよ一度施したコーティング
薬剤が必要なときリント布の表面力1ら2容出して分寓
廿してもられね4ゴならぬ。According to the present invention C, when the coating agent that has been applied once is needed, the surface force of the lint cloth can be removed by 1 to 2 volumes and distributed.
この要求を?岡たしたの力<(へ)の(’b頓ζこ示し
たコーチティング薬剤の調製であり〜り゛ラビアET]
”すζこ使用するインキの*占度と同J呈度ζこコーテ
ィング薬剤を調整することによって布の表面に厚さ20
p〜30=−のコーチインク−をJ%すことが可介ヒで
あることを発明したことである。This request? Oka Tashita's power <(he)'s ('btonζThis is the preparation of the coaching agent shown~rirabia ET]
By adjusting the coating agent to the same degree as the ink used, a thickness of 20 mm can be applied to the cloth surface.
It was invented that it is possible to reduce the coach ink of p~30=- by J%.
(e)千打功・を生の確認
実験例−1に」インクを示した表口く一本発明の方法に
より一一度リント布にコーティングされた薬剤は少量の
水分が存在すれば溶解−?8出して〜薬剤のI寺つ有効
・を生を確実ζこ発揮することを実験によって確認出来
たことである。(e) Confirmation of 1,000 hits in experimental example - 1. Front opening showing ink. The drug once coated on a lint cloth by the method of the present invention will dissolve in the presence of a small amount of moisture. ? We have been able to confirm through experiments that the drug's effectiveness is reliably demonstrated.
(f)安定・を生の確認
本発明により製造した薬剤コーティングリント布を室温
で6ケ月放置しておいたものを〜実W!nJ−1の方法
で有効・を生を石iかめると共に、液体クロマトグラフ
を用いて〜経時変化を確かめたところ〜製造時と全(変
わらな(1)agを耐忍しく尋たことである。(f) Confirmation of stability and rawness The drug-coated lint cloth produced according to the present invention was left at room temperature for 6 months. In addition to confirming the effectiveness using the nJ-1 method, we also used a liquid chromatograph to confirm changes over time. .
(g)多ピ辷を生の侑目忍
本発明により製造し一実yAタll−18こ用◇為た薬
剤コーティングリント布を12時間クローズド/”(ッ
チテスト法番こより〜ボランティア10イタB二対し試
験をしたところ陽を生と半り定されたものCよなく〜疑
陽を生と思われるもの1伊すで安全l主力9偏忍された
ことである。(g) The multi-layered cloth was manufactured according to the present invention and the drug-coated lint cloth was closed for 12 hours. On the other hand, when I tested it, it was decided that positive was half-life, and things that seemed to be positive and negative were found to be negative.
くト)発明の効果
本発明ζま〜皮膚患合トヵ1ら浸出〜漏出する生体の体
液C,:着目し〜その体液を水力−として活用すること
によって〜本来液体でしか有効を生を発揮し得なG)薬
剤を固体の4大聾で使用することに成功した点が何より
も大きな特徴である。Effects of the invention The present invention ζ ~ Leakage from skin lesions 1 ~ Leakage of living body fluids C: Focusing on ~ Utilizing the body fluids as hydraulic power ~ Exercising effects that are originally only available in liquids The most significant feature is that G) the drug was successfully used in the four major deafnesses.
その糸吉果〜医療の場で今迄思(、sもっ力)な力1っ
た用途力<5月発さねへその効果?tま今後益々皮膚疾
患りご■迄む人々を救ってマチくことになるだろう。That Itoyoshi fruit ~ Until now, I've been thinking about the power that has been used in the medical field <Is it the effect that will be released in May? In the future, more and more people will be saved and cured of skin diseases.
(1)液体の薬剤の取り扱G)の不便さくこζま′れや
すむ)〜運J舟楚〜携帯に不便を解決した。(1) The inconvenience of handling liquid drugs has been solved.
(2)液体の薬剤の秤量の不便さを解決した。(2) Solved the inconvenience of weighing liquid drugs.
(3)量産カベ可fJ詮であり一力へつイ呆存が容易で
ある。(3) It is possible to mass produce the wall, and it is easy to leave it alone.
(4)液イヒした薬剤の持つイヒ学自勺不安定・を生を
解決し〜経時0勺に安定なものカベ出来る。(4) Solve the problem of self-instability of the liquid drug and make it stable over time.
(5)医療の上品で〜薬剤の投薬と処置が一度に出来〜
fXヒ率イヒカ(図れる。(5) Medical elegance ~ Medication and treatment can be done at the same time ~
fX Hi rate Ihika (I can figure it out.
(6)救急用薬剤の剤型として大変適してむ)る。(6) It is very suitable as a dosage form for emergency drugs.
(7)奔び円のネリ用率力1妬(〜彷り径の軟膏等に上
ヒして同じ効果を求める土烏合−21斗が少なくてすむ
。(7) There are fewer people who seek the same effect by applying it to Tobien's Neri ointment.
第一図Cま一本発明の製造工程■坊簡11J−1)の略
図である。
第二図?、ま、コーチインク−薬剤をトレー中力1ら力
1き上クデ〜 リント布にイ寸着させるためのローラー
の斜視図
第三図!よ一本発明の薬剤コーティングリント布の展5
43fi明図(アルミ蒸着リント布)
第四図るま〜第三図の仔3分拡大断面8?i明図第五図
ζま一本発明の薬剤コーティングリント布の3党1男図
ユ リント布のロール
2 トレー
3コーテインダ薬剤
4表面がゴムのシーラー
5メツシユの24をBtuしたローラー6 ローラー
7 ローラー
8乾燥BOX
9 リント布巻上げローラー
a リント布
bアルミ箔
Cコーティング薬剤Figure 1 C is a schematic diagram of the manufacturing process of the present invention. Second figure? , Well, Coach Ink - The third perspective view of the roller for applying the drug to the lint cloth! Yoichi Exhibition of drug-coated lint fabric of the present invention 5
43fi clear drawing (aluminum vapor deposited lint cloth) 4th drawing - 3 minutes enlarged cross section of the 3rd drawing 8? Figure 5 Figure ζ Figure 1 Three parts of the drug-coated lint cloth of the present invention One figure Roll of lint cloth 2 Tray 3 Coating agent 4 Sealer with rubber surface 5 Roller with 24 Btu mesh Roller 6 Roller 7 Roller 8 Drying box 9 Lint cloth winding roller a Lint cloth b Aluminum foil C Coating agent
Claims (8)
布すると、皮膚患部から浸出、漏出した体液によって、
コーティングされた薬剤が溶出し、皮膚患部に直接薬効
が奏効する事を特徴とする、薬剤コーティングリント布
の製造法(1) When a drug is coated on the surface of a lint cloth and applied, body fluids seeping or leaking from the affected area of the skin can cause
A method for manufacturing drug-coated lint cloth, which is characterized by the elution of the coated drug and its medicinal effect directly on the affected skin area.
維布、あるいは、これらにアルミを蒸着したものである
特許請求の範囲第1項記載の方法(2) The method according to claim 1, wherein the lint cloth is gauze, cotton cloth, nonwoven fabric, collagen fiber cloth, or aluminum vapor-deposited thereon.
ロロフェン、アクリノール、塩化ベンゼトリウム、塩化
ベンザルコニウム、 グルコン酸クロルヘキシジン、ポリビニールピロリドン
、酢酸ビニール、塩酸アルキルポリアミノエチルグリシ
ン、 クロトリマゾール、硝酸ミコナゾール、硝酸エコナゾー
ル、臭化ドミフェン、インドメタシン、 ケトブロフェン、フルルビブロフェン、ジクロフェナッ
ク、フラジオマイシン、塩酸プロカイン、リドカイン、
アミノ安息香酸エチル、デキサメサゾン、 アドレノクローム、塩酸ジブカイン、ポリビニールアル
コール、インシュリン、シクロデキストリン、プロスタ
グランジン、塩化デリカニウム及びトリグルコ多糖から
1種または2種以上の薬物で調整した薬剤である特許請
求の範囲第1項記載の方法。(3) The drugs are iodoform, povidone-iodine, hexachlorophene, acrinol, benzethrium chloride, benzalkonium chloride, chlorhexidine gluconate, polyvinylpyrrolidone, vinyl acetate, alkylpolyaminoethylglycine hydrochloride, clotrimazole, miconazole nitrate, econazole nitrate, Domiphene bromide, indomethacin, ketobrofen, flurbibrofen, diclofenac, fradiomycin, procaine hydrochloride, lidocaine,
The claimed drug is a drug prepared with one or more drugs from ethyl aminobenzoate, dexamethasone, adrenochrome, dibucaine hydrochloride, polyvinyl alcohol, insulin, cyclodextrin, prostaglandin, delicanium chloride, and triglucopolysaccharide. The method described in Scope 1.
可能であり、かつ粘着テープとの組合せ等で使用可能で
ある、特許請求の範囲第1項記載の方法(4) The method according to claim 1, wherein the drug-coated lint cloth can be cut into any size and can be used in combination with adhesive tape, etc.
消毒を目的としている特許請求の範囲第1項記載の方法(5) Medicinal effects include local antipruritic, analgesic, anti-inflammatory, and sterilizing effects on the affected skin area.
The method according to claim 1, which is intended for disinfection.
技術を応用したもの及びキャスティング法、ロールコー
ター法等の基本技術及びその応用である特許請求の範囲
第1項記載の方法(6) The method according to claim 1, wherein the coating technology is an application of printing technology such as a gravure printing method, or a basic technology such as a casting method or a roll coater method, or an application thereof.
用医薬品、一般用医薬品としての製造許可承認を必要と
する範囲のものである特許請求の範囲第1項記載の方法(7) The method according to claim 1, wherein the drug-coated lint cloth is within the range that requires manufacturing permission and approval as a medical drug or over-the-counter drug as stipulated by the Pharmaceutical Affairs Law.
優れ、吸湿性、清潔性を具備条件とし得るものである特
許請求の範囲第1項及び第2項記載の方法(8) The method according to claims 1 and 2, wherein the lint cloth has a soft touch and is excellent in skin protection, and has hygroscopicity and cleanliness.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13312086A JPS62289515A (en) | 1986-06-09 | 1986-06-09 | Lint fabric having surface coated with drug |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13312086A JPS62289515A (en) | 1986-06-09 | 1986-06-09 | Lint fabric having surface coated with drug |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS62289515A true JPS62289515A (en) | 1987-12-16 |
Family
ID=15097257
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13312086A Pending JPS62289515A (en) | 1986-06-09 | 1986-06-09 | Lint fabric having surface coated with drug |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS62289515A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995012397A1 (en) * | 1993-11-06 | 1995-05-11 | Bayer Aktiengesellschaft | Plaster for treating nail mycoses |
-
1986
- 1986-06-09 JP JP13312086A patent/JPS62289515A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995012397A1 (en) * | 1993-11-06 | 1995-05-11 | Bayer Aktiengesellschaft | Plaster for treating nail mycoses |
WO1995012393A1 (en) * | 1993-11-06 | 1995-05-11 | LABTEC Gesellschaft für technologische Forschung und Entwicklung mbH | Plaster for the treatment of nail mycoses |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4481372B2 (en) | Bactericidal plastic sponge material | |
DE69032125T2 (en) | GEL Wound Dressing Compositions And Method For Using Them | |
US4563184A (en) | Synthetic resin wound dressing and method of treatment using same | |
EP2515869B1 (en) | Wound care products | |
TW200418531A (en) | Medical dressing containing antimicrobial agent | |
ES2657216T3 (en) | Skin or wound dressing for wet healing | |
PT1863469E (en) | A topical analgesic composition | |
WO2001047559A9 (en) | Patches for external use | |
JP2022523780A (en) | Antibacterial dressings, dressing components, and methods | |
BRPI0708204A2 (en) | absorbent polyurethane foam dressing | |
CN102427802A (en) | Medicinal cream prepared by using silver sulfadiazine and chitosan and preparation method thereof | |
US20050266081A1 (en) | Antimicrobial silver hydrogels | |
US20120064146A1 (en) | Wound care device | |
DE60207606T2 (en) | ARTICLES OF WOUND TREATMENT | |
RU2193896C2 (en) | Covering for wounds | |
US11376230B2 (en) | Wound care product | |
JPS62289515A (en) | Lint fabric having surface coated with drug | |
KR20100017345A (en) | Biocidic medical devices, implants and wound dressings | |
Dong et al. | A novel CHS/ALG bi-layer composite membrane with sustained antimicrobial efficacy used as wound dressing | |
JP2002104974A (en) | Hydrogel therapeutic agent for damaged skin | |
RU2270646C2 (en) | Dressing material | |
JPS6399866A (en) | Lint cloth having drug coated surface and its production | |
US7119246B2 (en) | Method of treating acne | |
RU2427379C1 (en) | Diabetic foot prevention and care composition | |
JPS6173665A (en) | Protection of wound by artificial skin |